- Hype & Hope Portal
- About Hype & Hope
- Contact Us
- Privacy
- Published by:Zoomedia, Inc.
Join our Mailing List
Feed Hype & Hope updates directly to your favorite news aggregator such as My Yahoo!, NewsGator or FeedDemon.
Published by Zoomedia, Inc.
Zoomedia is a leading communications agency dedicated to increasing our clients' value through insightful and imaginative creative programs for the life sciences industry.
For questions or comments about this site, please contact hypeandhope@zoomedia.com.
©2008 Zoomedia, Inc.
All rights reserved.
A Bottle-Nosed Approach to Personalized Medicine
Six years ago I attended a biotech conference in San Francisco. One of the panels that intrigued me most was entitled, "Personalized Medicine: to Market in Five Years." Certainly, everyone was talking about the New Era of Personalized Medicine and I attended to listen to as many different perspectives on emerging industry trends as possible. The panel was exciting, the potential for individualized medicine was here today and all we needed to do was interpret the genetic data we were generating by the bucket load and bring new products to market!Let's do it!
So how many clinical development people were there? None. How many commercial development or marketing people were there? One, just me. So how on earth were all these R&D and genomics folks going to get to market? I asked - there was a pregnant pause...
Okay, so now it's 2006. Last week I attended the Second...
A Bottle-Nosed Approach to Personalized Medicine
Six years ago I attended a biotech conference in San Francisco. One of the panels that intrigued me most was entitled, "Personalized Medicine: to Market in Five Years." Certainly, everyone...
Three Ways Congress Could Help Save Lives
Since the Democrats regained the House and the Senate, there have been many news articles posing the ways that Democrats and Congress could damage the pharmaceutical industry. The list...
Numerous Undiscovered Gene Alterations In Pancreatic And Brain Cancers Detected
HHMI investigators have detected a multitude of broken, missing, and overactive genes in pancreatic and brain tumors, in the most detailed genetic survey yet of any human tumor. Some of these genetic changes were previously unknown and could provide new leads for improved diagnosis and therapy for these devastating cancers.
>> Read the StoryMassive Gene Scan Finds Brain Tumor Clues
A sweeping survey of cancer genes has turned up previously unknown mutations that lead to brain cancer and possibly explain resistance to a common chemotherapy drug used to treat it, Boston researchers from a multi-center team report.
>> Read the StoryOSU to Host National Personalized Health Care Conference
The Ohio State University Medical Center has invited experts from across the country to discuss translating scientific breakthroughs in the laboratory to clinical health care practice during the national Personalized Health Care Conference on Oct. 16-17.
>> Read the StoryOncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development
Medelis, Inc., an oncology contract research organization providing complete oncology clinical trial design, management and execution, today published a free new downloadable abstract, “Preclinical Trials: A Nuanced Approach to Get Into the Clinic Faster,” an interview with Mike McGarry, Ph.D.
>> Read the StoryMolecular Breast Imaging Found More Tumors in Women with Dense Breasts
The results of a study conducted at the Mayo Clinic showed molecular breast imaging to be a more effective cancer screen for women with dense breasts.
>> Read the StoryDrug Stores Don’t See Progress for Electronic Drug-Pedigree Bill
New congressional legislation for track-and-trace drug pedigrees is unnecessary and probably will not move out of a House committee in the near future, according to an executive from the National Association of Chain Drug Stores (NACDS).
>> Read the StoryShould Medicare Pay for Genetic Testing?
This may be your last chance to tell the federal government whether Medicare should pay for a cutting-edge personalized medicine service.
>> Read the StoryBiotech Flourishes in Oro Valley
A key goal among Phoenix bioscience interests is to create a cluster of research companies that offer high-wage jobs and discover important breakthroughs.
>> Read the StoryLeading Geneticist to Write Book on Staying Well
Dr. Francis Collins, a leading geneticist in the United States and author of the best-selling “The Language of God,” is working on a book that promises “stunning new revelations about why we get sick; what it means to be healthy; how we can prevent disease” and medical treatment.
>> Read the StoryTracing Breast Cancer
The kidneys squeeze out more than a liter of urine each day. Over the past 13 years, Marsha Moses and her colleagues have been panning the amber liquid for proteins and other particles that might indicate the presence of cancer and other disease.
>> Read the StoryKRAS Developments and Implementation of Findings
The Holy Grail of oncology is the ability to predict which treatments will be effective for a given patient and spare the toxicity, time and expense of futile therapies. In colorectal cancer, tumor Kirsten ras (KRAS) gene mutational status has recently emerged as a biomarker of nonresponse to therapies targeting the epidermal growth factor receptor.
>> Read the StoryDTC Ad Bans, Limited Genetic Knowledge Spur Industry to Ramp Up MD Marketing
As the idea of personalized medicine begins to take hold in the public mind, personal genomics companies and diagnostics firms are ramping up efforts to market their tests to doctors, recognizing that physicians stand to be powerful mediators between the genetic testing industry and consumers.
>> Read the StoryHelix Health Founder Discusses Challenges Of Running a Personalized Medicine Practice
Helix Health Founder Steven Murphy touts his company as the first privately funded medical practice in the US to apply genetic and genomic expertise to determine an individual’s risk of developing common chronic diseases.
>> Read the StoryDesperate Search for Gift of Life
Even though chemotherapy often leaves her weak, Michelle Maykin is armed with a powerful weapon whenever she sets out to convince potential donors to join a national bone marrow registry — her beaming face.
>> Read the StorySan Bruno Company Banking on Cord Blood
Wendy and Steve Grant have made a $100 million business out of something that everyone is born with and is almost always thrown away: stem-cell rich blood from umbilical cords.
>> Read the StorySuccess Rate Rising of Transplants Using Donor Tissues
A team of surgeons gave 32-year-old Dave Robert Armstrong of Upland a hand, last July — literally.
>> Read the StorySchooling Ourselves on Sustainability
Educating students about the environment and sustainability has never been easy, particularly because the reductionist paradigm inherent in the disciplinary structure of education inherently conflicts with the broad scope of the field, and the mixed backgrounds of students entering the programs.
>> Read the StoryLexington Company has New Analytic Device
RainDance Technologies Inc. has come up with a revolutionary technology, the company says, that will change the way laboratory samples are analyzed for medical research and drug preparation.
>> Read the StoryToday the Index Value closed at $47.25, down -1.07 -- a loss of -2.21%.
The index value dropped to 12.9808 from 13.2747 with an associated index market cap of $309.315 Billion.
| Company | Ticker | Last | Change | % |
| Abbott Laboratories | ABT | $56.57 | -$1.36 | -2.35% |
| Affymetrix, Inc. | AFFX | $8.36 | -$0.19 | -2.22% |
| Amgen, Inc. | AMGN | $60.88 | -$2.22 | -3.52% |
| Bayer AG | BAY | $0.00 | $0.00 | 0 |
| Becton, Dickinson and Company | BDX | $85.78 | -$1.88 | -2.14% |
| Beckman Coulter Inc | BEC | $72.00 | -$2.43 | -3.26% |
| Bio-Rad | BIO | $104.69 | -$0.97 | -0.92% |
| Ciphergen Biosystem | CIPH | $0.00 | $0.00 | 0 |
| Dade Behring Hldgs Inc | DADE | $0.00 | $0.00 | 0 |
| Quest Diagnostics | DGX | $53.96 | -$0.57 | -1.05% |
| Genentech | DNA | $96.50 | -$1.18 | -1.21% |
| dnaprint genomics, Inc. | DNAG.OB | $0.00 | $0.00 | 0 |
| Epix Pharmaceuticals, Inc. | EPIX | $1.49 | -$0.13 | -8.02% |
| Genomic Health, Inc. | GHDX | $21.97 | -$0.60 | -2.66% |
| Gene Logic | GLGC | $0.00 | $0.00 | 0 |
| Invitrogen Corporation | IVGN | $41.15 | -$1.30 | -3.06% |
| Luminex Corporation | LMNX | $25.47 | -$0.61 | -2.34% |
| Monogram Biosciences, Inc. | MGRM | $0.75 | -$0.03 | -3.85% |
| Millipore | MIL | $72.94 | -$2.54 | -3.37% |
| Millenium Pharmaceuticals Inc. | MLNM | $0.00 | $0.00 | 0 |
| Nanogen, Inc. | NGEN | $0.34 | -$0.005 | -1.47% |
| OSI Pharmaceuticals | OSIP | $48.14 | -$1.19 | -2.41% |
| Sequenom, Inc. | SQNM | $22.90 | -$0.39 | -1.67% |
| TM Bioscience | TMC.TO | $10.10 | $0.00 | 0.00 |
| Ventana Medical Systems, Inc. | VMSI | $0.00 | $0.00 | 0 |
Last Close: Sep 4, 2008 17:15:01 PDT
This week's events
EuPAT
October 7, 2008Göteborg, Sweden
European BioPerspectives
October 7, 2008Hannover, Germany
View All:
> Stem Cells Events
> Personalized Medicine Events
> Clinical Trials Events
Advertisement
